T-DM1 works by attaching to the HER2 receptors on the surface of cancer cells. Once bound, the whole complex is internalized by the cell. Inside the cell, DM1 is released, where it disrupts microtubules, leading to cell cycle arrest and apoptosis. This targeted approach helps to reduce damage to healthy cells, minimizing side effects.